Ixchelsis
Ixchelsis is a UK-based, privately held clinical-stage biopharmaceutical company developing an oxytocin receptor antagonist for the treatment of premature ejaculation, founded in 2011 and operating with a small specialized team.
- Company typePrivate
- Founded2011
- HeadquartersSandwich, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Ixchelsis does
Ixchelsis is a privately held, clinical-stage biopharmaceutical company founded in 2011 and headquartered in Sandwich, United Kingdom. The company is developing an oxytocin receptor antagonist — a small-molecule therapeutic — intended for the treatment of premature ejaculation, a condition for which limited approved pharmacological options currently exist. The company operates as a single-asset specialist developer, concentrating its resources on advancing this lead compound through preclinical and clinical development.
The company has raised a disclosed total of $12,000,000 across two funding events, with the most recent round in December 2016 led by Pfizer Venture Investments and TVM Capital Life Science. An earlier 2013 transaction involved TVM Capital Life Science. The company is led by founder and CEO Gary Muirhead, with Liz Littlewood serving as Chief Operating Officer. Headcount is reported at 1-10 employees, consistent with a lean specialty biotech operating largely through outsourced CRO partnerships for clinical and regulatory work.
As a pre-commercial drug developer, Ixchelsis has no disclosed product revenue, no named customers or commercial partners, and no public pricing or licensing arrangements. The company's website (ixchelsis.com) currently displays only a security verification page with no substantive corporate disclosures. Its revenue model is therefore contingent on future out-licensing, partnership, or eventual product commercialization, none of which are documented in the available data. The business model is best characterized as capital-intensive R&D with binary outcomes tied to clinical and regulatory milestones for a single therapeutic asset.
Ixchelsis firmographics
Firmographics- Name
- Ixchelsis
- Website
- https://ixchelsis.com
- Company type
- Private
- Founded year
- 2011
- Headcount range
- 1–10 employees
- Short description
- Ixchelsis is a UK-based, privately held clinical-stage biopharmaceutical company developing an oxytocin receptor antagonist for the treatment of premature ejaculation, founded in 2011 and operating with a small specialized team.
- Ownership category
- akta.pro rank
Ixchelsis industry classification
Industry- Product category
- Sexual Health Pharmaceuticals
- NAICS
- Medicinal and Botanical Manufacturing (325411), Medical and Diagnostic Laboratories (62151), Medical and Diagnostic Laboratories (6215)
- SIC
- Medicinal Chemicals & Botanical Products (2833), Services-Medical Laboratories (8071), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Plasma-Derived Protease Inhibitors & Complement Modulators (e.g., C1 Esterase Inhibitor) (HLAIAHAF)
Keywords
Where Ixchelsis is headquartered
LocationHeadquarters
- HQ city
- Sandwich
- HQ country
- United Kingdom
- HQ region
- Europe
Markets served
Ixchelsis business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations
Ixchelsis product offering
Product offeringCore offering
Ixchelsis is a clinical-stage pharmaceutical R&D company developing an oxytocin receptor antagonist as a drug candidate for the treatment of premature ejaculation. The company's core activity is research, formulation, and clinical advancement of a small-molecule therapeutic targeting the oxytocin receptor pathway to address a male sexual health condition.
Differentiator
Problem solved
Functional benefit
Products and services
- Oxytocin receptor antagonist (lead drug candidate)
Companies that use Ixchelsis
Customer profileIdeal customer profiles1 record
Ixchelsis technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Ixchelsis partnerships and signals
Strategic signalRecent moves3 records
Expansion highlights2 records
Ixchelsis competitors and assessment
Company assessmentDirect peers
- Absorption Pharmaceuticals: Markets Promescent, a topical lidocaine-based spray for premature ejaculation sold OTC in the US. Comparable commercial positioning (lifestyle consumer health) for the same indication, with established brand and DTC distribution.
- Futura Medical: UK-listed specialty pharma developing Eroxon, a topical gel for erectile dysfunction. Closest publicly-traded UK small-cap comparable — same geography, similar scale, adjacent sexual-dysfunction indication, OTC commercial pathway.
- Plethora Solutions Holdings: UK-based specialty pharma that developed PSD502 (Fortacin), a topical anaesthetic spray approved in the EU for premature ejaculation. Most directly comparable single-indication PE developer with similar UK roots and small-cap profile.
- Apricus Biosciences (now Seelos Therapeutics successor assets): Developed Vitaros (alprostadil cream) for erectile dysfunction — adjacent sexual-health indication with similar regulatory, commercial, and OTC-Rx positioning considerations as an oxytocin antagonist for PE.
Broad incumbents
- Sprout Pharmaceuticals: Acquired by Valeant/Bausch Health after launching Addyi (flibanserin) for hypoactive sexual desire disorder. Reference case for a small biotech successfully bringing a sexual-dysfunction drug to market and exiting via strategic acquisition.
- AMAG Pharmaceuticals (acquired by Covis Pharma): Women's-health-focused specialty pharma with sexual-dysfunction and reproductive assets. Demonstrates the strategic acquirer archetype for small-cap sexual-health biotechs and provides exit-multiple context.
- Recordati: European specialty pharma with established sexual-health/urology franchise. Representative strategic acquirer profile for niche sexual-medicine assets and a useful benchmark for European commercial economics in this category.
Emerging players
- Palatin Technologies: Small-cap US biotech developing melanocortin receptor agonists for sexual dysfunction (e.g., bremelanotide for HSDD). Comparable in scale, business model (single-asset sexual health biotech), and reliance on strategic partnerships.
- Emotional Brain (EB Life Sciences): European biotech that developed Lybrido/Lybridos for female sexual dysfunction using a mechanism-based on-demand dosing approach. Comparable niche sexual-dysfunction biotech with on-demand pharmacology thesis.
- Endoceutics (Estetra SRL): Private mid-sized biotech focused on women's health and sexual dysfunction (e.g., E4/Estetrol programmes). Comparable private specialty-pharma model addressing an underserved sexual-medicine market.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Ixchelsis social profiles
Digital presenceIxchelsis financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ixchelsis leadership team
Management profileNumber of profiles
Profiles2 records
Ixchelsis funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ixchelsis M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ixchelsis
What does Ixchelsis do?
Ixchelsis is a clinical-stage pharmaceutical R&D company developing an oxytocin receptor antagonist as a drug candidate for the treatment of premature ejaculation. The company's core activity is research, formulation, and clinical advancement of a small-molecule therapeutic targeting the oxytocin receptor pathway to address a male sexual health condition.
When was Ixchelsis founded?
Ixchelsis was founded in 2011. It employs 1 to 10 people.
Where is Ixchelsis based?
Ixchelsis is headquartered in Sandwich, United Kingdom, in the Europe region.
Who are Ixchelsis's main competitors?
Direct peers on record are Absorption Pharmaceuticals, Futura Medical, Plethora Solutions Holdings and Apricus Biosciences (now Seelos Therapeutics successor assets). Broad incumbents are Sprout Pharmaceuticals, AMAG Pharmaceuticals (acquired by Covis Pharma) and Recordati. Emerging players are Palatin Technologies, Emotional Brain (EB Life Sciences) and Endoceutics (Estetra SRL).
Does Ixchelsis have an API?
No public API is recorded for Ixchelsis.
What industry is Ixchelsis in?
Ixchelsis's product category is Sexual Health Pharmaceuticals. Its primary akta.pro industry code is HLAIAHAF, Plasma-Derived Protease Inhibitors & Complement Modulators (e.g., C1 Esterase Inhibitor). Its NAICS code is 325411 and its SIC code is 2833.